Patent classifications
C12Y102/04001
Electrochemical Bioreactor Module and Engineered Metabolic Pathways for 1-Butanol Production with High Carbon Efficiency
A combination of an electrochemical device for delivering reducing equivalents to a cell, and engineered metabolic pathways within the cell capable of utilizing the electrochemically provided reducing equivalents is disclosed. Such a combination allows the production of commodity chemicals by fermentation to proceed with increased carbon efficiency.
Method of producing L-amino acids
Provided is a method of producing
METHOD OF PRODUCING L-AMINO ACIDS
Provided is a method of producing L-amino acids by using a recombinant coryneform microorganism in which the expression of a target gene is weakened by using a gene transcription inhibition method.
DECREASING LACTATE LEVEL AND INCREASING POLYPEPTIDE PRODUCTION BY DOWNREGULATING THE EXPRESSION OF LACTATE DEHYDROGENASE AND PYRUVATE DEHYDROGENASE KINASE
The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells. In one aspect, the invention provides a method comprising culturing cells expressing a) a small interfering RNA (siRNA) specific for a lactate dehydrogenase (LDH) and b) an siRNA specific for a pyruvate dehydrogenase kinase (PDHK). In another aspect, the invention provides cultured cells or vectors comprising an siRNA specific for a LDH and an siRNA specific for a PDHK.
METHOD FOR PRODUCING 3-HYDROXYPROPIONIC ACID AND OTHER PRODUCTS
This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a chemical product, which includes 3-hydroxypropionic acid.
Methods for producing designer esters and assessing alcohol acyltransferase specificity for ester biosynthesis
Methods of microbial screening for identifying alcohol acyltransferases for ester biosynthesis and submodules for ester pathways to produce butyryl-coenzyme A derived esters are disclosed. The method includes the introduction preselected plasmids into a respective host strain to form engineered microbes, in situ fermentation thereof followed by a colorimetric assay for quantification of production of the target ester. In situ fermentation includes inoculating each well of a microplate that have a culture media for producing target esters with one of the engineered microbes, adding an overlay of a solvent to each, and incubating the same. The colorimetric assay includes transfer of a quantity of the overlay from each well to respective clean wells of a new microplate, treatment of each well to form an iron-hydroxamic acid complex aqueous phase, centrifugation of the microplate, and measurement of the absorbance at 520 nm and comparison to a standard curve for the target ester.
Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions.
BIO-BASED PRODUCTION OF SUCCINIC ACID USING VIBRIO NATRIEGENS
This disclosure provides methods and genetically engineered strains of Vibrio natriegens, specifically developed for the bio-based production of succinate. Capitalizing on the rapid growth kinetics and highly efficient carbon metabolism of V. natriegens, this disclosure provides an environmentally friendly, scalable, and cost-effective alternative to traditional petrochemical methods for succinate production.
METABOLIC REPROGRAMING OF ADOPTIVELY TRANSFERRED T CELLS TO POTENTIATE ANTITUMOR RESPONSE
Disclosed herein are immune effector cells for use in adoptive cell transfer that have chemically- or genetically-inhibited PDHB (Pyruvate dehydrogenase E1 subunit beta) expression or activity. Also disclosed are methods of inhibiting or ablating PDHB expression in immune effector cells ex vivo and methods of using these cells to treat subjects with cancer. In some embodiments, the immune effector cells are further treated with a TIMS inhibitor or genetically engineered to ablate TIM3 expression. In some embodiments, the immune effector cells are further treated with a LAGS inhibitor or genetically engineered to ablate LAG3 expression. In some cases, the PDHB gene is disrupted by insertion of the gene encoding the chimeric receptor into the PDHB gene loci of the cell. Therefore, disclosed herein is a chimeric cell expressing a chimeric receptor.
SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE
System and method of producing a dimethylcyclooctane-based aviation fuel from isoprene includes culturing a genetically engineered microbe under suitable conditions to produce a first product including isoprene, dimerizing, using a transition metal-based catalyst, isoprene to form a second product including dimethylcyclooctadiene, and hydrogenating, using a hydrogenation catalyst, dimethylcyclooctadiene to form a third product including dimethylcyclooctane, wherein the genetically engineered microbe includes a heterologous nucleic acid construct encoding a peptide, the peptide having an activity configured to contribute to an enhanced production of isoprene.